CTRI/2024/08/071826招募中4 期
Outcome of Emicizumab Prophylaxis in Patients of Haemophilia A with or without Inhibitor An Early Experience from A Tertiary Care Hospital From Eastern India - NI
ESIPGIMSR ESIC Medical College and Hospital Joka Kolkata0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •All patients having severe Haemophilia A and moderate Haemophilia A with bleeding phenotype with or without inhibitor are included in the study
排除标准
- •Haemophilia B patients and patients of other coagulation disorders are excluded from the study
研究者
相似试验
尚未招募
4 期
A study about how well emicizumab prevents bleeding in haemophilia A patients and its overall impact on their health outcomesCTRI/2024/07/069770Rnt medical College
已完成
3 期
PHASE III STUDY OF EMICIZUMAB IN PATIENTS WITH ACQUIRED HEMOPHILIA A (AGEHA)Acquired hemophilia AJPRN-jRCT2080225056Chugai Pharmaceutical Co., Ltd.14
进行中（未招募）
1 期
Safety in Hemolytic PNH Patients Treated with Eculizumab: A Multi-center Open-label Research Design Study - SHEPHERDEUCTR2004-002795-42-IEALEXION PHARMACEUTICALS INCORPORATED97
进行中（未招募）
1 期
Safety in Hemolytic PNH Patients Treated with Eculizumab: A Multi-center Open-label Research Design Study - SHEPHERDparoxysmal nocturnal hemoglobinuriaMedDRA version: 7.0Level: PTClassification code 10034042EUCTR2004-002795-42-ESALEXION PHARMACEUTICALS INCORPORATED97
进行中（未招募）
1 期
Safety in Hemolytic PNH Patients Treated with Eculizumab: A Multi-center Open-label Research Design Study - SHEPHERDparoxysmal nocturnal hemoglobinuriaMedDRA version: 7.0Level: PTClassification code 10034042EUCTR2004-002795-42-GBALEXION PHARMACEUTICALS INCORPORATED97